北京若生智能科技有限公司
Drug Database
NI

nitroglycerin (nitroglycerin, Alza / Nitroderm / Nitroderm TTS)

✓ Approved

Johnson & Johnson Services, Inc. · 小分子 · 小分子

什么是 nitroglycerin？

nitroglycerin 是一种小分子，由Johnson & Johnson Services, Inc.研发。该药已获批，用于治疗相关适应症，给药途径：Topical、Transdermal。

药物档案

商品名nitroglycerin, Alza, Nitroderm, Nitroderm TTS
公司Johnson & Johnson Services, Inc.
药物类别小分子
给药途径Topical, Transdermal
状态Approved
来源： ClinicalTrials.gov, Johnson & Johnson Services, Inc.

治疗适应症

nitroglycerin 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Cardiac disordersAngina pectoris✓ Approved

相关研究文献

PubMedJournal of medicinal chemistry2026-09-10

Structure-Function Analysis of the Benzyloxy Moiety of the Delta-Opioid Receptor Positive Modulator BMS-986187: Identification of a Derivative with High Selectivity for the Delta-Opioid Receptor over the Mu-Opioid Receptor In Vitro and In Vivo.

Li Mengchu M, Zhang Sherrice S, Powell Alexander J AJ, Stewart Hannah C HC et al.

Positive allosteric modulators (PAMs) of the delta-opioid receptor (DOR) enhance endogenous opioid signaling while avoiding the convulsant liability of orthosteric agonists. However, the prototypical DOR-PAM, BMS-986187, also potentiates mu-opioid receptor (MOR) signaling, raising concerns regarding respiratory depression and abuse liability. Here, we report a structure-activity study of the benzyloxy moiety of BMS-986187 to improve selectivity for DOR over MOR, while retaining DOR-PAM potency. Fifty-two new analogues and 12 previously reported ones featuring mono- and disubstitution of the benzyl ring and phenyl-heterocycle replacements were synthesized and evaluated in β-arrestin2 recruitment assays. Ortho-substituted derivatives consistently enhanced DOR-PAM potency, although often increased MOR-PAM activity. One pyridyl derivative (compound 35) retained high DOR-PAM potency and efficacy (EC50 = 0.1 μM, Emax = 91%) with no detectable MOR activity. In mice, compound 35 enhanced DOR-mediated reversal of nitroglycerin-induced hyperalgesia, an effect absent in DOR-knockout mice, without enhancing MOR-mediated antinociception, demonstrating in vivo selectivity.

PMID 42720491
阅读全文 →
PubMedJournal of acute medicine2026-09-10

Profile and Outcomes of Patients Presenting With Sympathetic Crashing Acute Pulmonary Edema (SCAPE) to a Tertiary Care Emergency Department in North India: A Prospective Observational Study.

Sharma Ankit A, Bhardwaj Bharat Bhushan BB, Arora Poonam P, Mathew Roshan R et al.

Sympathetic crashing acute pulmonary edema (SCAPE) is a severe manifestation of acute heart failure, characterized by sudden pulmonary edema due to elevated sympathetic activity. This study aimed to describe the clinical profile, management, and short-term outcomes of patients with SCAPE presenting to a tertiary care hospital in North India. This prospective observational study described the clinical profile of patients with SCAPE who were managed with high-dose nitroglycerin (NTG). Sixty-two patients with a mean age of 49.4 years were enrolled, and 90.3% had one or more comorbidities. All patients exhibited signs of sympathetic excess and pulmonary edema on point-of-care ultrasound (POCUS). The treatment protocol included high-dose NTG and non-invasive ventilation (NIV). Male sex, chronic kidney disease, longer symptom duration, plethoric inferior vena cava on POCUS, higher initial lactate, and the need for hemodialysis were identified as predictors of poor outcomes in the univariate analysis. This study highlights that a protocol-based approach using high-dose NTG and NIV in managing SCAPE patients shows a favorable outcome, resulting in low rates of mechanical ventilation and mortality despite high comorbidity burden and ICU admission rates.

PMID 42719725
阅读全文 →
PubMedCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2026-09-09

Acute Inferior Myocardial Infarction with Anomalous Origin of the Right Coronary Artery, Myocardial Bridging and Fibro-Lipid Plaque.

Shen Jun J, Wu Yanming Y, Wang Biao B

We describe a 35-year-old male patient who had acute inferior myocardial infarction based on clinical signs and electrocardiographic abnormalities after experiencing sudden chest pain for 2 h. An abnormal origin of the right coronary artery (RCA) from the left coronary sinus was discovered by emergency coronary angiography, along with mild stenosis in the mid-RCA segment that persisted even after intracoronary nitroglycerin was administered. The mid-RCA lesion was identified by intravascular ultrasonography (IVUS) as a 48% stenotic fibro-lipid plaque with a lipid core and thin fibrous top. A minimum luminal diameter of 2.14 mm was found at the deformed RCA ostium with concomitant myocardial bridging. The patient experienced total symptom alleviation and an uneventful recovery after receiving dual antiplatelet therapy, intense lipid-lowering treatment, diltiazem for myocardial bridging, and stringent risk factor control. For long-term risk reduction, a multidisciplinary evaluation is planned for surgical of the coronary abnormality. In addition to highlighting the significance of tailored management approaches for congenital coronary anomalies combined with acquired vulnerable plaques, this case underscores the crucial role of multimodality imaging, particularly IVUS, in accurate etiological diagnosis and treatment decision-making for young patients with acute myocardial infarction (AMI) caused by complex coronary lesions.

PMID 42712015
阅读全文 →
PubMedWorld neurosurgery2026-09-09

Repurposing a Dual-Head Programmable Power Injector for Controlled Intra-Arterial Vasodilator Delivery During Cerebral Vasospasm Treatment.

Gandhi Om H OH, Almasri Sami S, Gaston Nicholas T NT, Rashad Mohammad S MS et al.

Cerebral vasospasm following aneurysmal subarachnoid hemorrhage remains a leading cause of morbidity and mortality. Endovascular treatment with intra-arterial vasodilators is established for medically refractory vasospasm, yet medication delivery relies on manual hand-syringe injection with limited control over infusion rate and volume. In this proof-of-concept technical note, we describe a workflow innovation repurposing a dual-head programmable power injector (Nemoto PRESS DUO elite, Nemoto Kyorindo) for simultaneous contrast administration and controlled vasodilator infusion during endovascular vasospasm treatment. One chamber delivers contrast for angiographic runs, while the other contains a triple vasodilator cocktail of verapamil, nicardipine, and nitroglycerin, delivered via the injector's programmable Infusion Mode at operator-defined flow rates and volumes. This closed-system, dual-chamber architecture eliminates tableside syringe exchanges, reduces the risk of air entrainment, and enables precise, reproducible multi-agent delivery. In our experience with 9 patients (12 treatment sessions), the injector-based workflow facilitated routine use of the triple vasodilator cocktail with angiographic improvement observed in all sessions. Fluoroscopy time, radiation dose, contrast volume, and total procedural duration did not differ significantly from those of a historical manual-injection cohort, which served as a procedural workflow reference. Because the manual cohort received a different vasodilator regimen without nicardipine, the two cohorts are pharmacologically unmatched and angiographic outcomes were not compared between groups. No procedural complications related to the delivery method occurred. These preliminary findings suggest the dual-head programmable injector provides a feasible, ergonomic, and reproducible closed-system workflow for intra-arterial vasodilator delivery during cerebral vasospasm treatment, with broader applicability to other intra-arterial drug delivery settings.

PMID 42716244
阅读全文 →
PubMedInternational journal of obstetric anesthesia2026-09-06

Total intravenous anesthesia for open fetal myelomeningocele repair: a case series from a single-center in Peru (2017-2025).

Lozano Marjorie Lisseth Calderón MLC, Gonzales Álvaro Renato Moreno ÁRM, Fernández Sergio Llanos SL

Open fetal myelomeningocele repair requires maternal general anesthesia and profound uterine relaxation. Total intravenous anesthesia may be an alternative to volatile anesthetics. We describe our anesthetic approach and maternal, fetal, surgical, and neonatal outcomes. We retrospectively reviewed 25 cases of open fetal myelomeningocele repairs performed from January 2017 to July 2025. The anesthetic protocol comprised target-controlled infusions of propofol and remifentanil guided by bispectral index monitoring, neuromuscular blockade, intravenous uterine relaxation, and intramuscular fetal atropine, fentanyl, and vecuronium. All 25 procedures were completed under total intravenous anesthesia without use of volatile anesthetics. Combined magnesium sulfate and nitroglycerin were used for uterine relaxation in 60% of cases. Fetal bradycardia occurred in one case (4%), and no cases of maternal pulmonary edema occurred. Median gestational age at delivery was 36 weeks. Total intravenous anesthesia combined with intravenous uterine relaxants was feasible for open fetal myelomeningocele repair in this case series.

PMID 42700585
阅读全文 →
PubMedJournal of vascular and interventional radiology : JVIR2026-09-06

Impact of spasmolytic cocktail and Glidesheath Slender on radial artery spasm in transradial cerebral angiography: A randomized factorial trial.

Deng Gang G, Liu Chenchen C, Wang Yihui Y, Ao Donghui D et al.

To evaluate the independent and interaction effects of prophylactic intra-arterial nitroglycerin-verapamil versus saline and a 6 Fr Glidesheath Slender versus a conventional 6 Fr sheath on clinical radial artery spasm during diagnostic transradial cerebral angiography. In this prospective, single-center, 2 × 2 factorial randomized trial, 255 patients undergoing diagnostic TRCA were assigned to prophylactic intra-arterial NV or saline and radial access with either GSS or conventional 6 Fr sheath (CS). The primary outcome was clinical RAS. Secondary outcomes included radial artery occlusion (RAO) and procedural outcomes. Clinical RAS occurred more frequently with GSS than with CS (33.9% vs 18.8%, P = .003). NV did not significantly reduce RAS compared with saline (29.7% vs 21.7%, P = .149). RAO was also higher with GSS (23.6% vs 11.7%, P = .022). After adjustment for prespecified covariates, GSS use remained associated with clinical RAS. In this exploratory randomized trial, prophylactic intra-arterial NV did not significantly reduce clinical RAS during diagnostic TRCA. GSS use was associated with higher rates of clinical RAS and RAO under the evaluated procedural conditions. These findings should be interpreted cautiously and require validation in future studies.

PMID 42702335
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多nitroglycerin